Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.56M | $-288.20M | $-1.08 |
| 2024 | $10.12M | $-220.66M | $-0.87 |
| 2023 | $1.70M | $-208.38M | $-1.20 |
| 2022 | $6.19M | $-148.84M | $-1.57 |
| 2021 | $1.51M | $-142.10M | $-1.97 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.20 per share
Typical surprise +6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.15 vs $-0.21beat
- Thu, May 14$-0.27 vs $-0.29beat
- Fri, Mar 27$-0.34 vs $-0.26miss
- Wed, Nov 12$-0.30 vs $-0.23miss
- Tue, Aug 12$-0.18 vs $-0.24beat
- Thu, May 8$-0.26 vs $-0.24miss
Estimates and results for AUTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
AUTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·4d ago·Positive
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Autolus Therapeutics Q2 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.
View source ↗